Anthem Biosciences IPO Listing: Stock Lists at 27% Premium Over IPO Price

Anthem Biosciences IPO Listing: A Phenomenal Debut with Over 26% Premium – A Testimony to Business Strength and Market Confidence

Anthem Biosciences, a leading player in the Contract Research, Development, and Manufacturing Organization (CRDMO) sector, made an impressive entry into the Indian stock market with its ₹3,395.79 crore Initial Public Offering (IPO).

The IPO, which was open for subscription from July 14 to July 16, 2025, received overwhelming interest from investors, underscoring the company’s growth prospects and market potential.

Today, the company’s shares made a striking debut on the stock exchanges, showcasing not just strong demand, but also a positive outlook on its financial health and future growth trajectory.

IPO Details and Investor Demand

The Anthem Biosciences IPO generated immense investor enthusiasm, with an overall subscription rate of over 67 times, indicating that the company’s value proposition resonated strongly with the market.

The IPO was issued at a price of ₹570 per share, and the first day of listing proved to be a testament to the company’s healthy market positioning and growth potential.

Upon listing, Anthem Biosciences shares surged to ₹723.10 on the Bombay Stock Exchange (BSE) and ₹723.05 on the National Stock Exchange (NSE), translating to a 26% premium over the issue price.

The stock didn’t stop there—it continued its upward momentum throughout the trading day, reaching a high of ₹746.70 on BSE.

By the close of trading, the share price stood at ₹730.35 on BSE, representing a 28.13% listing gain for investors who had participated in the IPO.

Employee Benefits: A Strong Upside for Anthem’s Team

The company also extended special benefits to its employees, who received shares at a discounted rate of ₹50 per share.

This not only rewards the team for their contribution to the company’s growth but also strengthens employee loyalty, aligning their financial interests with the long-term success of the company.

This additional benefit for employees speaks to Anthem Biosciences’ commitment to its workforce and the alignment of incentives as the company scales its operations.

Subscription Breakdown: A Clear Market Vote of Confidence

Anthem Biosciences’ IPO subscription data clearly highlights the broad-based confidence across various investor categories.

The Qualified Institutional Buyers (QIBs), including large mutual funds, pension funds, and foreign institutional investors, were particularly bullish on the stock, with their portion being subscribed 192.80 times.

This strong demand from institutional investors signals a robust belief in Anthem’s business model and its future growth prospects.

The Non-Institutional Investors (NIIs), comprising high-net-worth individuals (HNIs) and family offices, also displayed confidence, with their share of the IPO being subscribed 44.70 times.

Retail investors, who typically represent the broader public, subscribed 5.98 times the portion allotted to them, indicating a healthy level of interest from everyday investors. Lastly, employees, whose portion of the offer was subscribed 6.99 times, also showed strong participation in the offering.

The overwhelming response from all segments of investors not only highlights the attractiveness of Anthem’s growth story but also suggests a significant level of market confidence in the company’s future.

IPO Structure: Offer for Sale (OFS) Mechanism

While the size of the IPO was significant, it’s important to note that Anthem Biosciences did not issue any new shares as part of this offering.

Instead, the IPO was structured as an Offer for Sale (OFS), where existing shareholders (including promoters and early investors) sold their shares to the public.

As a result, the company itself will not receive any proceeds from the IPO. The entire ₹3,395.79 crore raised will go to the selling shareholders.

This strategic move means that there is no dilution of equity for the company, and it will retain full control over its business operations.

Anthem Biosciences continues to focus on enhancing its operations, increasing its market share, and expanding its global footprint without giving up control of its business.

This structure is seen as a way to provide liquidity to existing shareholders, while keeping the company’s capital structure intact.

The total number of shares offered was 5,95,75,319 shares, each with a face value of ₹2. The company’s decision to utilize the OFS route rather than issuing new shares highlights a pragmatic approach to raising capital while preserving its financial flexibility.

About Anthem Biosciences: A Leader in CRDMO Services

Founded in 2006, Anthem Biosciences is a contract research, development, and manufacturing organization (CRDMO) that offers a broad range of services to the global pharmaceutical and biotechnology industries.

The company provides end-to-end solutions, including research, development, and manufacturing services for drugs, biologics, and nutraceuticals.

Its portfolio spans across probiotics, enzymes, peptides, nutritional actives, vitamin analogs, and biosimilars, which are critical components in the development of modern medicines.

Anthem has successfully established a strong reputation in the CRDMO space, particularly among biotech startups and global pharmaceutical giants.

The company’s ability to offer comprehensive solutions, coupled with its focus on high-quality standards, has allowed it to carve out a niche in a highly competitive and rapidly evolving sector.

In terms of intellectual property, Anthem has made notable strides in innovation. As of September 2024, the company holds one patent in India and seven internationally, with an additional 24 patent applications pending.

This innovative pipeline positions Anthem as a leader in drug development and manufacturing, ensuring that it remains at the cutting edge of biotechnology advancements.

Strong Financial Performance: A Robust Growth Trajectory

Anthem Biosciences has demonstrated remarkable financial growth over the past few years, driven by a combination of solid revenue generation, strategic partnerships, and a diversified portfolio of products and services.

In the financial year 2023, Anthem reported a net profit of ₹385.19 crores. This grew to ₹367.31 crores in FY 2024, and the company is projecting further growth, with ₹451.26 crores in net profit for FY 2025. These figures are a testament to Anthem’s growing market presence and operational efficiency.

Revenue has also seen consistent growth, with the company achieving a Compound Annual Growth Rate (CAGR) of more than 30% over the last few years.

In FY 2025, Anthem’s total revenue reached ₹1,930.29 crores, further solidifying its position as one of the leading players in the CRDMO sector.

The Road Ahead: A Bright Future

The strong listing performance of Anthem Biosciences is a clear reflection of its solid business fundamentals, growing financial health, and expanding global presence.

With a diverse portfolio of products, robust revenue growth, and a commitment to innovation, the company is well-positioned to continue its upward trajectory in the coming years.

The market’s positive response to Anthem Biosciences’ IPO is a clear indication that investors believe in the company’s long-term vision.

As Anthem continues to expand its reach and capabilities, it is expected to remain a significant player in the global pharmaceutical and biotechnology sectors.

In conclusion, Anthem Biosciences’ IPO debut represents not just a successful listing, but also a glimpse into the company’s promising future.

Investors, both institutional and retail, have placed their faith in Anthem’s ability to generate strong returns, backed by its solid growth prospects, strong financial performance, and a diversified product portfolio.

As the company embarks on the next chapter of its journey, the stock market will closely watch how Anthem Biosciences continues to deliver on its potential.